[Descriptive epidemiology of cancer of the pancreas].

Bull Cancer

Faculté de Médecine, Dijon, France.

Published: May 1990

Cancer of the pancreas is a relatively common malignancy in France, where it represents 10% of all digestive tract cancers. Over the world, there is little variation in incidence rates; Europe, North America, South America, Oceania and parts of Asia represent high risk areas. The regions with the lowest incidence rates are India, mid-western countries and Africa. In most countries, pancreatic cancer incidence rates increased between 1950 and 1965; however little change in incidence has been observed over the past 20 years. Pancreatic cancer occurs more frequently in males than in females in all age groups. No consistent differences have been identified in urban/rural distribution or in socioeconomic status. Studies of migrant populations and some religious groups indicate that environmental factors are of overwhelming importance in determining the incidence of pancreatic cancer in a given population. In the same areas, difference in incidence has been reported among various ethnic groups: in the United States the rate is higher in Blacks than in Whites, in New Zealand in Maoris and Polynesians than in Whites, in Israel in Jews than in non-Jews. This data leads us to the conclusion that diet is of importance in pancreatic cancer etiology. No premalignant lesion has been clearly identified. Particular attention has been paid to diabetes mellitus and chronic pancreatitis, but a firm conclusion cannot be drawn. Some potentially valuable clues for clarifying the etiology of pancreatic cancer have been found by way of descriptive epidemiology. In view of the severe prognosis of the disease, there is an urgent need for further aetiological studies in order to develop effective methods of prevention.

Download full-text PDF

Source

Publication Analysis

Top Keywords

pancreatic cancer
20
incidence rates
12
cancer
7
incidence
6
pancreatic
5
[descriptive epidemiology
4
epidemiology cancer
4
cancer pancreas]
4
pancreas] cancer
4
cancer pancreas
4

Similar Publications

Purpose: Adaptive radiotherapy accounts for interfractional anatomic changes. We hypothesize that changes in the gross tumor volumes identified during daily scans could be analyzed using delta-radiomics to predict disease progression events. We evaluated whether an auxiliary data set could improve prediction performance.

View Article and Find Full Text PDF

Background: The role of adjuvant radiotherapy in pancreatic cancer following radical surgery remains a subject of of controversy. This study aimed to more accurately screen pancreatic patients who benefit from adjuvant radiotherapy.

Methods: Clinicopathologic characteristics of patients with resectable pancreatic cancer were collected from the Surveillance, Epidemiology, and End Results (SEER) database (2004-2015).

View Article and Find Full Text PDF

Purpose: Patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) have been noted to face increased cancer incidence. Yet, the impact of concomitant renal dysfunction on acute outcomes following elective surgery for cancer remains to be elucidated.

Methods: All adult hospitalizations entailing elective resection for lung, esophageal, gastric, pancreatic, hepatic, or colon cancer were identified in the 2016-2020 National Inpatient Sample.

View Article and Find Full Text PDF

Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive and lacks effective therapeutic options. Cancer cells frequently become more dependent on splicing factors than normal cells due to increased rates of transcription. Terminal uridylyltransferase 1 (TUT1) is a specific terminal uridylyltransferase for U6 small nuclear RNA (snRNA), which plays a catalytic role in the spliceosome.

View Article and Find Full Text PDF

ERBB4 selectively amplifies TGF-β pro-metastatic responses.

Cell Rep

January 2025

MOE Key Laboratory of Biosystems Homeostasis & Protection, and Zhejiang Provincial Key Laboratory of Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang 310058, China; Center for Life Sciences, Shaoxing Institute, Zhejiang University, Shaoxing, Zhejiang 321000, China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310058, China; The Second Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310009, China. Electronic address:

Transforming growth factor β (TGF-β) is well known to play paradoxical roles in tumorigenesis as it has both growth-inhibitory and pro-metastatic effects. However, the underlying mechanisms of how TGF-β drives the opposing responses remain largely unknown. Here, we report that ERBB4, a member of the ERBB receptor tyrosine kinase family, specifically promotes TGF-β's metastatic response but not its anti-growth response.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!